Paolo Mannelli

Publication Activity (10 Years)

Years Active: 2018-2022
Publications (10 Years): 6

Top Topics

Electronic Health Record

Clinical Decision Support

Top Venues

The American journal on addictions

Addiction (Abingdon, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Paolo Mannelli, Antoine B Douaihy, Sarah C Akerman, Anna Legedza, James Fratantonio, Abigail Zavod, Maria A Sullivan
Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting. The American journal on addictions 31 (2) (2022)
Li-Tzy Wu, William S John, Udi E Ghitza, Aimee Wahle, Abigail G Matthews, Mitra Lewis, Brett Hart, Zach Hubbard, Lynn A Bowlby, Lawrence H Greenblatt, Paolo Mannelli, null null
Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National Drug Abuse Treatment Clinical Trials Network. Addiction (Abingdon, England) 116 (7) (2021)
Sandra D Comer, Paolo Mannelli, Danesh Alam, Antoine Douaihy, Narinder Nangia, Sarah C Akerman, Abigail Zavod, Bernard L Silverman, Maria A Sullivan
Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens. The American journal on addictions 29 (4) (2020)
Adam Bisaga, Paolo Mannelli, Maria A Sullivan, Suzanne K Vosburg, Peggy Compton, George E Woody, Thomas R Kosten
Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies. The American journal on addictions 27 (3) (2019)
Paolo Mannelli, Li-Tzy Wu
Commentary on Winhusen et al. (2019): Substance use disorders, chronic diseases, and electronic health records-a paradigm for screening and intervention. Addiction (Abingdon, England) 114 (8) (2019)
Paolo Mannelli, Marvin Swartz, Li-Tzy Wu
Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. The American journal on addictions 27 (6) (2018)